GSK plc (ETR:GS71)
Germany · Delayed Price · Currency is EUR | Market Cap | 91.75B +39.8% |
| Revenue (ttm) | 37.54B +4.0% |
| Net Income | 6.68B +84.9% |
| EPS | 1.63 +86.6% |
| Shares Out | n/a |
| PE Ratio | 13.74 |
| Forward PE | 10.54 |
| Dividend | 0.77 (3.35%) |
| Ex-Dividend Date | May 14, 2026 |
| Volume | 8,388 |
| Open | 23.06 |
| Previous Close | 22.98 |
| Day's Range | 22.87 - 23.25 |
| 52-Week Range | 15.32 - 26.14 |
| Beta | 0.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial numbers in GBP Financial StatementsNews
GSK reports Jemperli single arm trial met its primary objective
GSK (GSK) plc announced “positive” interim results from the registrational phase II AZUR-1 trial of Jemperli in patients with stage II/III mismatch repair deficient/microsatellite instability-high loc...
GSK's Jemperli meets main goal in mid-stage rectal cancer trial
GSK said on Monday its cancer drug Jemperli met the primary goal of a mid-stage trial, with a clinically significant rate of patients showing no detectable signs of cancer for one year or more after...
GSK: Hansoh Pharma's Ris-Rez Shows Survival Benefit In Lung Cancer Trial
(RTTNews) - Hansoh Pharmaceutical Group, the licensor of GSK's investigational therapy Ris-Rez, announced positive Phase III results from its ARTEMIS-008 study in China, marking a major milestone in s...
GSK Achieves Phase 3 Trial Success for Risvutatug Rezetecan in Lung Cancer
GSK Achieves Phase 3 Trial Success for Risvutatug Rezetecan in Lung Cancer
GSK Achieves Key Milestone with Ris-Rez in Lung Cancer Trial
GSK Achieves Key Milestone with Ris-Rez in Lung Cancer Trial
GSK's targeted cancer therapy shows positive results in late-stage study
British drugmaker GSK's experimental drug for treating patients with advanced or relapsed small-cell lung cancer showed positive results in a late-stage trial on Friday.
GSK says Hansoh Pharma announces positive phase 3 results for Ris-Rez in China
GSK (GSK) plc licensor Hansoh Pharmaceutical Group announced that ARTEMIS-008, its pivotal phase III trial evaluating risvutatug rezetecan, or Ris-Rez, in patients with advanced or relapsed small-cell...
GSK price target raised to 1,950 GBp from 1,900 GBp at Deutsche Bank
Deutsche Bank raised the firm’s price target on GSK (GSK) to 1,950 GBp from 1,900 GBp and keeps a Hold rating on the shares.
Alector (ALEC) Shares Drop 13% Following Termination of GSK Collaboration
Alector (ALEC) Shares Drop 13% Following Termination of GSK Collaboration
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
Alector said on Wednesday that GSK had terminated their neuroscience collaboration agreement covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks.
Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs
Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China unit had secured rights to market two respiratory drugs from British company GSK in mainland China.
GSK upgraded to Hold from Reduce at HSBC
HSBC upgraded GSK (GSK) to Hold from Reduce with a price target of 1,860 GBp, up from 1,500 GBp. The key risk for the stock was a large patent cliff…
A Look at GSK PLC (GSK) After 4.6% Gain -- GF Value $43.94 vs Price $53.66
A Look at GSK PLC (GSK) After 4.6% Gain -- GF Value $43.94 vs Price $53.66
GSK (GSK) Has a Vaccines-and-Specialty-Medicines Mix Bigger Than a Patent-Expiry Debate
GSK (GSK) still gets pulled back into a familiar investor argument: how much of the equity story is simply a... The post GSK (GSK) Has a Vaccines-and-Specialty-Medicines Mix Bigger Than a Patent-Expir...
GSK Initiates Tender Offer for Nuvalent Shares
GSK Initiates Tender Offer for Nuvalent Shares
GSK announces commencement of tender offer to acquire Nuvalent
GSK (GSK) announced that Harmony Row Acquisition Co., a direct wholly-owned subsidiary of GlaxoSmithKline, which is an indirect wholly-owned subsidiary of GSK, has commenced a tender offer to purchase...
Spero: FDA Approves Utebzi, The First Oral Carbapenem For Complicated UTIs In Adults; Stock Up
(RTTNews) - GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the U.S. FDA has approved Utebzi (tebipenem pivoxil) as the first and only oral carbapenem antibiotic for adults with complicated...
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for ...
GSK Secures FDA Approval for Utebzi, First Oral Carbapenem for UTIs
GSK Secures FDA Approval for Utebzi, First Oral Carbapenem for UTIs
GSK Gains FDA Approval for New Oral Antibiotic Utebzi
GSK Gains FDA Approval for New Oral Antibiotic Utebzi
GSK, Spero Therapeutics announce FDA approval of Utebzi
GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the Food and Drug Administration has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections including ...
US FDA approves GSK's oral antibiotic for drug-resistant UTIs
The U.S. FDA has approved GSK's oral antibiotic to treat complicated urinary tract infections, the regulator said on Wednesday, giving patients a new treatment option against drug-resistant...
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.
Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC
Biotech investors are far more selective than they were during the pandemic-era boom, JPMorgan's top EMEA healthcare investment bankers told CNBC. Many biotech companies are now pursuing a dual-track...
GSK to Acquire Nuvalent for $10.6 Billion
GSK to Acquire Nuvalent for $10.6 Billion